Non-Medullary Thyroid Carcinoma
Conditions
Keywords
Thyroid cancer, Digoxin, Autophagy, Redifferentiation, Radio-iodine refractory
Brief summary
Non-medullary thyroid carcinoma has a good prognosis in most patients. However, a small subset of patients nevertheless develop metastatic or locally advanced and unresectable disease which in some cases also becomes radioiodine refractory. In these patients treatment options are very limited. Earlier cell line and animal studies have shown that digoxin can reinduce radioiodine uptake in non-medullary thyroid cancer. This study serves as a proof of principle study to assess the possibility of digoxin to reinduce radioiodine uptake in adult humans with metastatic or locally advanced non-medullary radioiodine refractory thyroid carcinoma.
Interventions
DRUGDigoxin tablet
Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged \>70 years or with body weight \<55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg. After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted.
Sponsors
Radboud University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
10 participants with radioiodine refractory metastatic or locally advanced non-medullary thyroid carcinoma will enroll in this study. All participants will be treated according to the same protocol.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Non-medullary thyroid carcinoma * Having undergone total thyroidectomy and at least 1 treatment with \[131\]sodium iodine (NaI) * Presence of local or metastatic disease, radiologically proven. A minimum of 1 target lesion (at least 1cm for soft tissue and 1.5cm for lymph nodes) must be present. * Radioiodine refractory disease; at least one lesion without therapeutic relevant uptake at previous post-therapeutic scintigraphy and/or negative diagnostic \[123\]NaI-scan. * The target lesion must not be eligible for local treatments. * Hematologic lab values should be at least: absolute neutrophil count \>1.4x10\^9/liter, hemoglobin\>5.5mmol/liter, thrombocytes \>99x10\^9/liter
Exclusion criteria
* Creatinine clearance \<50ml/min and/or active kidney disease * Cardiac arrhythmias * Electrolyte disorder * Concomitant drugs that interfere with digoxin metabolism such as P-glycoprotein inductors or inducers, including but not limited to penicillamine, sulfasalazin, tipranavir, amiodarona, diltiazem, itraconazole, ketoconazole, kinidin, lapatinib, propafenon, vemurafenib, verapamil, azithromycin, clarithromycin, erythromycin, roxithromycin, chloroquin, ciclosporin, anti hepatitis C drugs, anti-HIV drugs, hydroxychloroquine. * Pregnancy, lactating or breast-feeding women. * Having undergone a procedure with iodine contrast agent within the last 3 months. * Prior therapy with radioactive iodine \<6 months prior to participation. * External beam radiation therapy \<4 weeks prior to participation. * Having undergone chemotherapy or targeted therapy \<4 weeks prior to participation. * Eastern Cooperative Oncology Group (ECOG) score \>2. * Use of other investigational drugs within 4 weeks preceding the first dose of digoxin treatment. * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to digoxin. * Uncontrolled intercurrent illness that would limit compliance with the study requirements. * Unwillingness or inability to comply with study and follow-up procedures. * Other active malignancies other than basal cell carcinoma. Malignancies that have been in complete remission over 2 years are not considered active malignancies. * Rapidly progressive disease in which urgent start with systemic therapy is required.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reinduction of radioiodine uptake in target lesion | 3 weeks | At baseline and after 3 weeks of digoxin treatment, a scintigraphy scan will be conducted. Reinduction of radioiodine uptake is defined as enough uptake that a treatment with high-dose radioactive iodine is possible. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Beneficial effects of high-dose radioactive iodine treatment after reinduction | 6 months | Participants with reinduction of radioiodine uptake in the target lesion will be offered a treatment with high-dose radioactive iodine, according to the guidelines for the treatment of thyroid carcinoma. The beneficial effects of this treatment will be measured after 6 months with a computertomography scan and will be described using the RECIST criteria. |
| Safety of digoxin treatment | 3 weeks | All serious adverse events (SAE) occuring during the digoxin treatment will be described. |
Countries
Netherlands
Outcome results
None listed